- The goal is to identify and develop predictive biomarker panels to guide therapy — including combination therapy — for each patient based on the molecular composition of their tumor.
- These discoveries will then be used to better inform the simultaneous drug discovery in Core 2 above — as any markers that are identified as predicting response and/or resistance will be screened by the MD Anderson team for drugs or rational combinations of drugs.
- The identification of molecular biomarkers which predict drug response as well as those that will predict resistance to targeted therapy will help guide a more successful and rational treatment strategy for GBM patients.
